Sutro Biopharma Stock Price, News & Analysis

Sutro Biopharma (NASDAQ: STRO) reported Q3 2025 results and program updates on Nov 6, 2025. Key developments include U.S. FDA IND clearance for STRO-004 with first patient dosing expected before year-end and preclinical safety to 50 mg/kg in non-human primates. The company highlighted advancing dual-payload ADC programs and collaboration progress with Astellas, including an IND-enabling tox study initiated in Q1 2025. As of Sept 30, 2025, cash, cash equivalents and marketable securities totaled $167.6M, with an expected cash runway into at least mid-2027, aided by cost reductions, restructuring, and expected near-term milestone payments.

Sutro Biopharma (NASDAQ: STRO) will host a virtual Research & Development Day on Wednesday, November 12, 2025 to present its platform innovation and next‑generation ADC pipeline.

The live webcast begins at 7:00 AM PT / 10:00 AM ET; investors can access the audio webcast at the company's investor relations events page and an archived replay will be posted after the event.

Sutro Biopharma (NASDAQ: STRO) will participate at the 16th Annual World ADC Conference in San Diego, November 3-6, 2025. Sutro plans multiple presentations and panels showcasing preclinical data on site-specific, high-DAR dual-payload ADCs, immunostimulatory ADCs, cell-free antibody manufacturing, and the discovery and development of STRO-006, a Topo1-ADC targeting integrin beta-6.

Scheduled presenters include Daniel Calarese, Gang Yin, Venkatesh Srinivasan, Krishna Bajjuri, Alice Yam, and Hans-Peter Gerber, who will join panel discussions and talks across November 3-5, 2025. Presentation materials will be posted in Sutro’s Clinical/Scientific Presentation and Publication Highlights on www.sutrobio.com after the event.

Sutro Biopharma (NASDAQ: STRO), an oncology company focused on antibody drug conjugates (ADCs), announced a significant organizational restructuring to extend its cash runway into mid-2027. The restructuring involves a workforce reduction of approximately one-third of employees.

The company aims to prioritize the advancement of its three ADC programs and research collaborations. The extended runway will support key milestones, including the planned announcement of initial clinical data from STRO-004, their next-generation Tissue Factor-targeting exatecan ADC in 2026, and the initiation of clinical studies for at least one additional ADC program.

Sutro Biopharma (NASDAQ: STRO) reported its Q2 2025 financial results and business highlights, showcasing significant progress in its ADC pipeline. The company ended Q2 with $205.1 million in cash, providing runway into early 2027. Revenue surged to $63.7 million, up from $25.7 million in Q2 2024.

Key developments include preparations for STRO-004's first-in-human trial in H2 2025, advancement of STRO-006, and progress in dual-payload ADC programs. The company secured a $7.5 million milestone payment from Astellas following an IND-enabling toxicology study. Additionally, Sutro appointed Greg Chow as CFO and established a research collaboration with the FDA to enhance ADC regulatory standards.

Sutro Biopharma (NASDAQ: STRO) has announced a significant research collaboration with the FDA to advance regulatory standards for Antibody Drug Conjugates (ADCs). The partnership will utilize Sutro's proprietary XpressCF® technology to develop reference materials and enhance analytical methods for ADC drug development.

The collaboration involves Sutro working with the FDA's Office of Pharmaceutical Quality (OPQ) to jointly lead study design and selection of target antigens, payload-linkers, and drug conjugation sites. The initiative aims to improve quality assessments and regulatory standards for both approved ADCs and those in development, with results to be published upon completion.

Sutro Biopharma (NASDAQ: STRO) has appointed Greg Chow as Chief Financial Officer, effective June 2, 2025. Chow brings over 25 years of executive leadership experience in corporate finance, capital markets, and drug development operations. He previously served as Chief Financial and Business Officer at NodThera and held CFO positions at Freenome Holdings and Frontier Medicines. At Aptose Biosciences, he raised over $225 million and led the company's dual listing on Nasdaq and TSX. As part of his appointment, Chow received inducement grants including a restricted stock unit award for 100,000 shares and options to purchase 275,000 shares of Sutro's common stock, with specific vesting schedules.

Sutro Biopharma (NASDAQ: STRO) reported Q1 2025 financial results and announced strategic changes. The company has shifted focus to its next-generation ADC portfolio, discontinuing luvelta development. Key highlights include: $249.0 million in cash/equivalents (runway into early 2027), revenue of $17.4 million, and plans for three INDs in the next 3 years. The lead candidate STRO-004, a Tissue Factor ADC, is planned for clinical studies in 2H 2025. Significant restructuring includes a 50% headcount reduction and manufacturing facility decommissioning by year-end 2025. The company received a $7.5 million milestone payment from Astellas collaboration. Q1 expenses included $64.9 million in R&D/G&A and $21.0 million in restructuring costs.

Sutro Biopharma (NASDAQ: STRO), a company specializing in antibody drug conjugates (ADCs) for oncology, has announced its participation in two upcoming investor conferences. The company will present at The Citizens Life Sciences Conference in New York from May 7-8, 2025, and the BofA Securities 2025 Health Care Conference in Las Vegas from May 13-15, 2025. Webcasts of both presentations will be available on Sutro's website investor relations section, with replays accessible for at least 30 days after each event.